ALT Valuation

Altimmune Inc

Add to Watchlist

Advanced Chart

3.905

-0.055(-1.389%)1D

Overview
Forecast
Valuation
Earnings

ALT Relative Valuation

ALT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALT is overvalued; if below, it's undervalued.

Historical Valuation

Altimmune Inc (ALT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.76. The fair price of Altimmune Inc (ALT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.96

Fair

-3.09

Trailing

Forward

-1.48

EV/EBITDA

Altimmune Inc. (ALT) has a current EV/EBITDA of -1.48. The 5-year average EV/EBITDA is -2.67. The thresholds are as follows: Strongly Undervalued below -6.57, Undervalued between -6.57 and -4.62, Fairly Valued between -0.71 and -4.62, Overvalued between -0.71 and 1.24, and Strongly Overvalued above 1.24. The current Forward EV/EBITDA of -1.48 falls within the Historic Trend Line -Fairly Valued range.

-1.41

EV/EBIT

Altimmune Inc. (ALT) has a current EV/EBIT of -1.41. The 5-year average EV/EBIT is -3.16. The thresholds are as follows: Strongly Undervalued below -7.79, Undervalued between -7.79 and -5.48, Fairly Valued between -0.85 and -5.48, Overvalued between -0.85 and 1.47, and Strongly Overvalued above 1.47. The current Forward EV/EBIT of -1.41 falls within the Historic Trend Line -Fairly Valued range.

119147.29

Altimmune Inc. (ALT) has a current PS of 119147.29. The 5-year average PS is 21788.94. The thresholds are as follows: Strongly Undervalued below -75059.55, Undervalued between -75059.55 and -26635.31, Fairly Valued between 70213.18 and -26635.31, Overvalued between 70213.18 and 118637.43, and Strongly Overvalued above 118637.43. The current Forward PS of 119147.29 falls within the Strongly Overvalued range.

-3.54

P/OCF

Altimmune Inc. (ALT) has a current P/OCF of -3.54. The 5-year average P/OCF is -2.09. The thresholds are as follows: Strongly Undervalued below -42.89, Undervalued between -42.89 and -22.49, Fairly Valued between 18.30 and -22.49, Overvalued between 18.30 and 38.70, and Strongly Overvalued above 38.70. The current Forward P/OCF of -3.54 falls within the Historic Trend Line -Fairly Valued range.

-3.50

P/FCF

Altimmune Inc. (ALT) has a current P/FCF of -3.50. The 5-year average P/FCF is -5.70. The thresholds are as follows: Strongly Undervalued below -10.86, Undervalued between -10.86 and -8.28, Fairly Valued between -3.12 and -8.28, Overvalued between -3.12 and -0.53, and Strongly Overvalued above -0.53. The current Forward P/FCF of -3.50 falls within the Historic Trend Line -Fairly Valued range.

Altimmune Inc (ALT) has a current Price-to-Book (P/B) ratio of 2.09. Compared to its 3-year average P/B ratio of 2.65 , the current P/B ratio is approximately -21.23% higher. Relative to its 5-year average P/B ratio of 2.45, the current P/B ratio is about -14.94% higher. Altimmune Inc (ALT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -22.37%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -20.01% , the current FCF yield is about -100.00% lower.

2.09

P/B

Median3y

2.65

Median5y

2.45

-24.45

FCF Yield

Median3y

-22.37

Median5y

-20.01

Competitors Valuation Multiple

The average P/S ratio for ALT's competitors is 0.00, providing a benchmark for relative valuation. Altimmune Inc Corp (ALT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Rocket Pharmaceuticals Inc

Loss

343.13M

DSGN.O

Design Therapeutics Inc

Lineage Cell Therapeutics Inc

Loss

96.38%

369.94M

Performance Decomposition

Market capitalization of ALT decreased by 35.50% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 5.00K to 5.00K.

The secondary factor is the Margin Expansion, contributed -10.12%to the performance.

Overall, the performance of ALT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

0.00%

5.00K → 5.00K

Revenue Growth

-10.12%

-492.80K → -442.92K

Margin Expansion

-25.38%

-4.53 → -3.38

P/E Change

-35.50%